Stock AWY0 PERCHERON THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Percheron Therapeutics Limited Börse Stuttgart

Equities

AWY0

AU0000317281

Delayed Börse Stuttgart
Other stock markets
 07:05:24 27/06/2024 BST 		5-day change 1st Jan Change
0.0485 EUR +1.25% Intraday chart for Percheron Therapeutics Limited -3.23% +39.24%
06-17 Percheron Therapeutics Appoints CFO MT
06-03 Percheron Therapeutics Names Chief Medical Advisor MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Percheron Therapeutics Appoints CFO
MT
Percheron Therapeutics Names Chief Medical Advisor
MT
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%
MT
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate
MT
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102
MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Dimerix Appoints Nonexecutive Chair
MT
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited
CI
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels
MT
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million
MT
Antisense Therapeutics Appoints CEO/Managing Director
MT
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023
CI
Antisense Therapeutics Limited Announces Management Changes
CI
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%
MT
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK
CI
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%
MT
Antisense Therapeutics Appoints CEO/Managing Director
MT
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023
CI
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PER Stock
  4. AWY0 Stock
  5. News Percheron Therapeutics Limited